Faculty of 1000 evaluation for Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

2013 ◽  
Author(s):  
Ana Maria Gonzalez-Angulo
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Phase 2 ◽  
Single Group ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2 -amplified early stage breast cancer: a single-group, open-label, phase 2 study

2013 ◽  
Vol 14 (11) ◽  
pp. 1121-1128 ◽  
Author(s):  
Stephen E Jones ◽  
Rufus Collea ◽  
Devchand Paul ◽  
Scot Sedlacek ◽  
Anne M Favret ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Phase 2 ◽  
Single Group ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

scholarly journals Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

2011 ◽  
Vol 17 (21) ◽  
pp. 6905-6913 ◽  
Author(s):  
Richard S. Finn ◽  
Carmelo Bengala ◽  
Nuhad Ibrahim ◽  
Henri Roché ◽  
Joseph Sparano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Single Agent ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document